COVID-19: WHERE ARE WE NOW, WHERE ARE GOING, AND HOW TO COMMUNICATE THIS TO YOUR SCHOOL COMMUNITY

Ingrid T. Katz, MD, MHS
Associate Faculty Director | Harvard Global Health Institute
Associate Professor | Harvard Medical School
Associate Physician | Brigham and Women's Hospital

MA DEPT OF PUBLIC HEALTH: COVID DASHBOARD



Source: Commonwealth of Massachusetts

HEALTH OUTCOMES FOR CHILDREN



Source: American Academy of Pediatrics

- Children can become infected but become severely ill much less than adults

- Forward transmission from children: still uncertain

- Balance of child health outcomes:
  - Obesity, undernutrition
  - Mental health and substance use
  - Physical and emotional abuse
  - Academic and social/emotional development

- MA DESE (total school-associated cases, completeness not clear):
  - Dec 17-23: 0.53% of staff, 0.12% of students
  - Need additional data from DPH and DESE about in-school transmission

OVERVIEW OF VACCINES

MODERNA

- Authorized for emergency use in US, EU, UK, Canada, more
- **2** doses, **4** weeks apart
- mRNA platform
- 94.1% efficacy
- Recommended for ages 18+
- Registered early Dec to begin trials for ages 12-17
- Common side effects: pain, swelling, redness in arm; chills, headache, tiredness in body

PFIZER-BIONTECH

- Authorized for emergency use in US, EU, Canada, Singapore, more
- **2** doses, **3** weeks apart
- mRNA platform
- 95% efficacy
- Recommended for ages 16+ but began enrollment for ages 12+ in Oct
- Common side effects: pain, swelling, redness in arm; chills, headache, tiredness in body

OXFORD-ASTRAZENCA

- Authorized for emergency use in UK, Argentina, Mexico, India
- In Phase 2 and 3 trials
- **2** doses, **4** weeks apart
- Adenoviral platform
- 62% - 90% efficacy depending on dose

JOHNSON & JOHNSON

- In Phase 3 trials
- **1** dose
- Adenoviral platform
- Efficacy unknown
- If approved, to be distributed in US, UK
- Interim data to be available end of Jan 2021

VACCINE DISTRIBUTION

"100m shots in the first 100 days"

– President Elect Joe Biden

Biden Administration plans for **immediate release of available covid vaccines**

Contrasts current distribution plan of **guaranteed second dose**

Biden/Harris Administration to combat COVID with seven-point plan

22 million doses distributed to states since December, **under 33% have been administered**

MASSACHUSETTS COVID VACCINE DISTRIBUTION

CURRENTLY IN PHASE ONE

JAN 11TH, 2021:
FIRST RESPONDERS BEGAN RECEIVING FIRST DOSE OF VACCINATIONS



Source: Commonwealth of Massachusetts

- **TEACHERS** BEGIN RECEIVING VACCINATIONS DURING **PHASE TWO** FROM FEBRUARY TO APRIL
- SIMILAR PRIORITY PLANS IN **NH, ME**
- PHASE 2 TBD IN **CT, VT, RI**

EQUITY CONSIDERATIONS

In the US & MA:
- Black, Latinx & Indigenous communities: higher rates of COVID-19 and severe illness – includes children and educators

In the US:
- BIPOC students less often have option for in-person school than white students
- When offered, choose in-person school less often than white families

Reducing risk of COVID-19 infection can facilitate a more balanced choice based on other factors

"Districts serving mostly students of color are more likely to start online"



Data from 667 districts
Sept 2020

Source: AP/Chalkbeat

INEQUITIES IN VACCINE DISTRIBUTION

To combat inequities, many states are reserving vaccines for communities that have been disproportionately impacted by the pandemic

Tennessee

Committed to setting aside 5% of vaccine supply for areas with high scores on a CDC social vulnerability index

Massachusetts

To combat inequities, 20% additional vaccines allocated to communities that have experienced disproportionate COVID burden and high social vulnerability

California

Gov. Newsom vowed "because of the impact they have felt disproportionately" during the pandemic, officials are working to ensure communities of color are "disproportionately benefited"

MASKS ON OR OFF?

CONTINUE TO WEAR MASKS!

- No data showing vaccine prevents spread or transmission
- Vaccinated individual could still be asymptomatic and contagious
- Vaccine reduces COVID symptoms
- Data indicates masking (and other mitigation strategies) dramatically reduce transmission



SCREENING ASYMPTOMATIC STUDENTS & STAFF

Additional layer of protection



COMMUNICATING THIS TO YOUR SCHOOL COMMUNITY




QUESTIONS?

Why are teenagers and kids usually less susceptible to COVID19 than adults?

Scientists don't know for sure yet, but they have a hypothesis



What does it mean that a vaccine is over 90% effective?

There is a difference between effectiveness and efficacy

- Efficacy is what we know from a clinical trial
- Effectiveness is what we will know in a real world setting

So, we currently know that the vaccine has an efficacy rate of over 90%

Is there a cure for COVID19?

Viruses are really hard to "cure" because they are not technically alive, but instead target the "machinery" inside human cells



On Friday, December 11, the U.S. Food and Drug Administration granted Emergency Use Authorization for Pfizer's COVID-19 vaccine. Now Pfizer can begin working with state governments to get the vaccine to the people!

But how do we decide who gets the vaccine first?

BREAKOUT ROOMS: Think like a policy maker!

As a group, discuss who you think should get the COVID19 vaccine first: healthcare workers, first responders, the elderly or people with underlying conditions. Make sure are able to explain your choice!

THANK YOU!